GlobeNewswire Inc | Jan 6, 2021 04:01PM EST

January 06, 2021

NASHUA, N.H., Jan. 06, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD),a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will participate in the 10thAnnual LifeSci Partners Corporate Access Event,January 6-8and 11-14, 2021.

Michael Klein, Chairman and CEO, will host 1x1 meetings and will participate in a panel, Innovations in Cancer Diagnostics, on Thursday, January 7th at 4pm EST.

Mr. Kleins focus in diagnostics will be on iCADs newly launched ProFound AI Risk offering. This new breast cancer screening capability is the first and only commercially available clinical decision support tool that provides an accurate 2-year risk estimation based solely on a screening mammogram. Compelling research published in Radiology concluded that the ProFound AI Risk model is effective at identifying women at high likelihood of being diagnosed with breast cancer within two years of a negative screening mammogram and in possible need of supplemental screening.

To register to listen to the presentation or to request a meeting, visit: http://lifesci.events/LifeSci2021

About iCAD, Inc. Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visitwww.icadmed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

Certain statements contained in this News Release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For example, when the Company discusses the potential of ProFound AI Risk and its relationship with Change Healthcare, the benefits of the Companys products, and clinical plans and updates, it is using forward-looking statements. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Companys ability to achieve business and strategic objectives, increase sales and acceptance of products, adoption by CMS of a new payment model, and that such model will prove beneficial to the Company, which is not assured, implement expansion plans, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, to successfully defend itself in litigation matters, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; the effects of a global pandemic, and other risks detailed in the Companys filings with the Securities and Exchange Commission. The words believe, demonstrate, intend, expect, estimate, will, continue, anticipate, likely, seek, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.comand on the SECs website at http://www.sec.gov.

Contact:Media Inquiries:Amy Cook, iCAD +1-925-200-2125acook@icadmed.com

Investor Relations:Jeremy Feffer, LifeSci Advisors+ 1-212-915-2568jeremy@lifesciadvisors.com